Digital therapeutics (DTx) startup Dopavision has raised funding to develop its lead product, an app designed to slow the progression of myopia – or short-sightedness – in children or adole
Digital startup Dopavision has raised cash in a seed funding round backed by Boehringer Ingelheim, to develop a smartphone-based digital therapy for myopia (short-sightedness).
While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change